Case Study 24.1 — One Research Line, Three Destinations

The situation

A research program sets out to solve a specific, defensible problem: ultraviolet light causes tanning, and ultraviolet light causes skin cancer. If the melanocyte can be persuaded to make pigment without the ultraviolet, you get the cosmetic outcome that people want and the photoprotection that dermatologists want, without the DNA damage that produces the disease.

That is not a frivolous goal. It is a rational attempt to decouple a desired effect from a harm that is normally inseparable from it.

The program pursues the obvious route. The natural signal to the melanocyte is a peptide — α-MSH, cleaved from proopiomelanocortin. Natural α-MSH is a poor drug: short-lived, nonselective, and degraded quickly. So the program makes analogs, using the standard peptide-engineering toolkit of Chapter 4: substitute residues to resist proteolysis, cyclize the molecule to lock a shape, introduce a D-amino acid to defeat stereospecific enzymes. It produces short, cyclic, protease-resistant melanocortin agonists that are far more potent and far longer-lived than the hormone they were modeled on.

They tan people. The chemistry worked.

And during that work, unexpected effects on sexual arousal are observed. That observation is taken seriously and a separate development program follows.

Thirty-odd years later, the same research line has produced three distinct objects in the world:

One. Afamelanotide (melanotan I) — an approved drug, used to increase pain-free light exposure in erythropoietic protoporphyria, a rare disorder in which visible light causes severe burning pain. Randomized trials, regulatory approval in multiple jurisdictions, specialist supervision, a narrow indication that its mechanism fits exactly.

Two. Bremelanotide (PT-141) — an approved drug, used for hypoactive sexual desire disorder in premenopausal women. Two randomized placebo-controlled trials, validated instruments, a modest but statistically significant effect, common nausea, and an indication that excludes most of the people who have heard of it.

Three. Melanotan II — not approved anywhere, widely sold, used for cosmetic tanning. No completed randomized human efficacy or safety trials. A published body of case reports describing darkening and enlarging moles, eruptive melanocytic lesions, and melanoma in users. Structurally, it differs from bremelanotide at essentially one terminus of a seven-residue ring.

Three destinations. One origin. One receptor family.

What makes this a case study rather than an anecdote

The temptation is to read this as a story about serendipity — chance favoring the prepared mind, as the epigraph has it. That reading is not wrong, but it is the shallow half of what is here.

The deeper content is that the same molecular knowledge produced a legitimate drug, a second legitimate drug for an unrelated condition, and an unregulated product with a safety signal — and nothing about the chemistry distinguishes the three. What distinguishes them is entirely downstream of the molecule: which condition was targeted, whether trials were run, whether a regulator reviewed the data, whether the population was defined, and whether anyone is looking at the patient's skin.

Every argument you will ever encounter that runs "this compound is closely related to an approved drug, therefore it is credible" is refuted by this single research line. Melanotan II is closely related to two approved drugs. It has neither's evidence and neither's oversight.

There is one more layer, and it is the one most often missed. The gray-market compound is not the failed branch of the program. It is, arguably, the branch that most nearly achieved the program's original stated goal — a tan without ultraviolet. What it never acquired was the thing that turns a pharmacological effect into a medicine: a defined population, a measured endpoint, a comparator, a safety database, and someone accountable for what is in the vial.

Discussion questions

1. The chapter's 🧬 The Molecule callout notes that bremelanotide and melanotan II differ at essentially one functional group on a seven-residue ring, and that this changes the balance of receptor subtype activity. Using §24.2, explain why that small structural change produces a substantially different clinical profile — and then state what general lesson this offers about arguing from structural similarity. How would you respond to someone who says "it's basically the same molecule as the approved one"?

2. The origin story involves an unexpected observation of sexual arousal during a tanning program. Chapter 5 §5.2 says that uncontrolled single observations are near-useless for establishing that something works. But this observation led to an approved drug. Reconcile those two facts. What exactly did the anecdote accomplish, what did it not accomplish, and what work did the intervening thirty years do?

3. Melanotan II arguably achieved the original program's stated goal more directly than either approved drug did — it produces a tan without ultraviolet. Yet it is rated ❌ and afamelanotide is rated ✅, and both are melanocortin agonists that stimulate melanocytes. List everything that separates them. Then say which item on your list you consider most important, and whether any of them are features of the molecules themselves.

4. The case describes the tanning goal as "not frivolous" — decoupling a cosmetic outcome from a carcinogenic exposure is a rational aim. Yet the compound that pursued it most directly acts by stimulating the cell type melanoma arises from. Discuss whether the original goal was well-posed. Is there a version of "tanning without ultraviolet" that avoids this problem entirely, and if so, what does that suggest about the compound's place in the market?

5. Both approved drugs from this line have narrow indications: one rare disease, one specific diagnosis in one hormonal-status group. §24.5 argues that a narrow ✅ is often more trustworthy than a broad one. Explain that argument, then consider the counter-case: is there anything lost when a research line that produced broadly active compounds ends up with only narrow approvals? Who bears that loss?

6. Imagine you are asked to write a 200-word explanation of this research line for a general audience — a magazine sidebar, say. Write it. Then examine what you produced: which of the three destinations did you give the most space to, and why? What would a version written by someone selling melanotan II emphasize, and what would it omit? Compare the two and identify the specific sentences where the framing does the work.